Intermune Eyes Settlement Over Off-Label Marketing

Law360, New York (July 28, 2006, 12:00 AM EDT) -- Biotechnology company Intermune Inc. is preparing to pay as much as $30 million to settle allegations from federal prosecutors that it illegally promoted a drug for a use not approved by the U.S. Food and Drug Administration.

The U.S. Department of Justice began probing the Brisbane, Calif.-based company in 2004 after a former sales representative claimed she was fired for not taking part in off-label marketing—encouraging nonapproved uses of a drug.

The drug at the center of the controversy, Actimmune, currently has FDA approval for use...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.